Physical activity as a predictor of fremanezumab response in chronic migraine – the Phy-Fre-Mig study

Abstract Background The relationship between physical activity (PA) and migraine is insufficiently understood. Studies have not analysed levels of PA or Time Sitting (TS) during preventive treatment, nor the role these might play in the response to preventive treatment. Methods An observational, lon...

Full description

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Álvaro Sierra-Mencía, Andrea Recio-García, David García-Azorín, Antonio José Molina de la Torre, Isabel Ros González, Ángel Luis Guerrero-Peral
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Subjects:	Exercise Sedentary behaviour Migraine disorders Antibodies, Monoclonal
Online Access:	https://doi.org/10.1186/s10194-025-01965-w

Similar Items

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
by: A.Y. Timokhovich, et al.
Published: (2024-10-01)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-03-01)

Fremanezumab in the treatment of migraines: evidence to date
by: Robblee J, et al.
Published: (2019-08-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
by: Root S, et al.
Published: (2023-02-01)

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine
by: G. N. Belskaya, et al.
Published: (2024-02-01)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
by: Christopher Kjaer Cullum, et al.
Published: (2023-08-01)

Fremanezumab in real-life clinical practice: specialized headache center experience
by: Yu. E. Azimova, et al.
Published: (2024-06-01)

A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months
by: Shiho Suzuki, et al.
Published: (2025-06-01)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
by: Kenta Kashiwagi, et al.
Published: (2023-02-01)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
by: Bixi Gao, et al.
Published: (2020-05-01)

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
by: Piero Barbanti, et al.
Published: (2023-03-01)

Efficacy and continuability of 675 mg fremanezumab administration over 2 years
by: Shohei Yoshida, et al.
Published: (2025-03-01)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
by: Seiya Ohtani, et al.
Published: (2023-11-01)

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
by: Piero Barbanti, et al.
Published: (2024-03-01)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
by: Shiho Suzuki, et al.
Published: (2023-07-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021-03-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
by: Andrea Lovato, et al.
Published: (2023-08-01)

Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
by: Máté Héja, et al.
Published: (2025-04-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

The course of headache after the end of treatment with erenumab in patients with episodic and chronic migraine
by: Anna A. Garmanova, et al.
Published: (2024-05-01)

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
by: Victor Obach, et al.
Published: (2023-11-01)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-05-01)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-04-01)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
by: Raffaele Ornello, et al.
Published: (2021-03-01)

Comparative Clinical Efficacy Study between Erenumab and Fremanezumab
by: Raquel Fresquet, et al.
Published: (2022-11-01)

Migraine treatment: the doors for the future are open, but with caution and prudence
by: Abouch V. Krymchantowski, et al.

Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review
by: Patricia Pozo-Rosich, et al.
Published: (2024-11-01)

Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01)

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
by: Charly Gaul, et al.
Published: (2024-10-01)

Reversion of chronic to episodic migraine in working age and botulinum toxin‐resistant patients treated with fremanezumab: A real‐life study
by: Juan Tudela‐Tomas, et al.
Published: (2024-07-01)

Emerging Pharmacological Treatments for Migraine in the Pediatric Population
by: Luigi Francesco Iannone, et al.
Published: (2022-04-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01)

Increased MRI-based Brain Age in chronic migraine patients
by: Rafael Navarro-González, et al.
Published: (2023-10-01)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
by: Raffaele Ornello, et al.
Published: (2019-10-01)